51 active not recruiting, 12 completed, 11 recruiting, 5 terminated. 84 Phase 2, 15 Phase 1, 1 Phase 3.
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 500 | 2025-03-18 | 2026-10-20 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | Yuanquan Yang | 40 | 2024-07-09 | 2026-09-28 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 42 | 2023-09-28 | 2026-07-31 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-05-08 | 2026-07-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-02 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2022-11-14 | 2026-09-25 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma Antineoplastic Vaccine, Sargramostim, Pembrolizumab - Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Suspended | University of California, Davis | 77 | 2021-01-13 | 2026-06-29 |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration - Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Tianhong Li | 3 | 2020-10-30 | 2026-08-10 |
| Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia Extension of Community Health (ECHO) Telementoring Clinic, In-Country Workshops, Professional Oncology Educations Programs - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 312 | 2020-08-24 | 2026-09-14 |
Showing 20 of 84. Sign in to see all of them.
Lymphoma (36) · Multiple Myeloma (35) · Hematologic Neoplasms (22) · Neoplasm Metastasis (20) · Glioma (12) · Lymphoma, Non-Hodgkin (11) · Neuroblastoma (11) · Ependymoma (10) · Hepatoblastoma (10) · Histiocytosis, Langerhans-Cell (10) · Neuroectodermal Tumors, Primitive, Peripheral (10) · Rhabdoid Tumor (10) · Wilms Tumor (10) · Central Nervous System Neoplasms (9) · Medulloblastoma (9)
Neoplasms (77) · Neoplasms by Histologic Type (59) · Hemic and Lymphatic Diseases (49) · Neoplasms by Site (49) · Immune System Diseases (48) · Immunoproliferative Disorders (48) · Lymphoproliferative Disorders (48) · Lymphatic Diseases (47) · Hematologic Diseases (37) · Cardiovascular Diseases (36) · Vascular Diseases (36) · Blood Protein Disorders (35) · Hemorrhagic Disorders (35) · Hemostatic Disorders (35) · Neoplasms, Plasma Cell (35)
Specimen Handling (32) · Biopsy (31) · Magnetic Resonance Spectroscopy (28) · X-Rays (11) · Nuclear Medicine Department, Hospital (9) · Nivolumab (8) · Phantoms, Imaging (6) · palbociclib (6) · trametinib (6) · Crizotinib (5) · olaparib (5) · adavosertib (4) · copanlisib (4) · erdafitinib (4) · larotrectinib (4)
National Cancer Institute (NCI) (61) · M.D. Anderson Cancer Center (11) · OHSU Knight Cancer Institute (3) · Haihua Yuan (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · Sameek Roychowdhury (1) · Tianhong Li (1) · University of California, Davis (1) · Yuanquan Yang (1)
United States (81) · Puerto Rico (13) · Canada (4) · Australia (2) · Guam (1)
Sriram Yennu (4) · David S Hong (3) · Filip Janku (3) · Aung Naing (2) · Funda Meric-Bernstam (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Nilofer S Azad (2) · Patricia M LoRusso (2) · Shivaani Kummar (2) · Timothy A Yap (2) · A P Chen (1) · Aaron S Mansfield (1) · AeRang Kim (1)
PMID 31401903, PMID 32463741, PMID 26586415, PMID 26602013, PMID 31533818, PMID 31765263, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33048619, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33591402, PMID 33770291, PMID 34241781, PMID 34331589, PMID 34486544, PMID 34725215, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35363510, PMID 35618285, PMID 35999229, PMID 36351402, PMID 36469840, PMID 36765881, PMID 37053535, PMID 37322121, PMID 37568622, PMID 37934000, PMID 38591867, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39298716, PMID 39384194, PMID 39666929, PMID 39693587, PMID 39773433, PMID 39863139, PMID 39913886, PMID 40139261, PMID 40153687, PMID 40212844, PMID 40580957, PMID 40865033, PMID 41066729, PMID 41143139
U10CA180820 (38), U24CA196172 (21), U10CA180886 (11), UM1CA186688 (5), UM1CA186689 (5), P30CA093373 (2), ZIABC011078 (2), P30CA016056 (1), P30CA060553 (1), P30CA069533 (1), R01CA164333 (1), R21NR016737 (1), UM1CA081457 (1), UM1CA186644 (1), UM1CA186704 (1)